Christophe Massard

机构：Université Paris-Saclay, Institut Gustave Roussy, Centre Eugène Marquis · ORCID：0000-0001-5505-0564

发表论文 1161 篇 · 总被引 25317 次 · h-index 79

代表论文

VEGF-A blockade overcomes liver metastases resistance to chemoimmunotherapy in patients with advanced non-squamous NSCLC (2026 · Journal for ImmunoTherapy of Cancer · 被引 1)
Clinical toxicity of ADCs and ICI–ADC combinations: mechanisms, patterns and management (2026 · Nature Reviews Clinical Oncology)
Supplementary Table S7 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors (2026)
Supplementary Table S3 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors (2026)
Supplementary Table S5 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors (2026)
Supplementary Table S11 from AZD8701, an Antisense Oligonucleotide Targeting FOXP3 mRNA, as Monotherapy and in Combination with Durvalumab: A Phase I Trial in Patients with Advanced Solid Tumors (2026)